Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 365,893,888
  • Shares Outstanding, K 2,682,902
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 36-Month Beta 0.68
  • Price/Sales 4.42
  • Price/Cash Flow 14.05
  • Price/Book 5.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 2.09
  • Number of Estimates 7
  • High Estimate 2.15
  • Low Estimate 1.99
  • Prior Year 2.06
  • Growth Rate Est. (year over year) +1.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.00 +8.87%
on 01/24/19
136.41 -0.23%
on 02/15/19
+5.40 (+4.13%)
since 01/18/19
3-Month
121.00 +12.47%
on 12/24/18
148.99 -8.66%
on 12/04/18
-11.64 (-7.88%)
since 11/19/18
52-Week
118.62 +14.73%
on 05/29/18
148.99 -8.66%
on 12/04/18
+2.94 (+2.21%)
since 02/16/18

Most Recent Stories

More News
Fortive Announces Proposed Offering of Convertible Senior Notes

Fortive Corporation ("Fortive") (NYSE: FTV) today announced that it proposes to offer, subject to market factors and other conditions, $1.25 billion in aggregate principal amount of its Convertible...

JNJ : 136.08 (-0.22%)
FTV : 80.97 (-1.01%)
United States Hip Reconstruction Market Size, Trends and Forecasts (2019-2023): Dominant Players are Zimmer Biomet Holdings, Johnson & Johnson, Stryker Corporation and Smith & Nephew - ResearchAndMarkets.com

The "The US Hip Reconstruction Market: Size, Trends and Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

ZBH : 123.80 (+0.12%)
SYK : 186.10 (-0.39%)
JNJ : 136.08 (-0.22%)
Visiongain Report Analyses Leading Players Within the Vaccines Manufacturers Market

The global vaccines market has witnessed strong growth in past few years. The top 5 manufacturers in the global vaccines market are: Merck & Co., Inc., Sanofi, Pfizer Inc., GlaxoSmithKline PLC, and Johnson...

JNJ : 136.08 (-0.22%)
MRK : 79.64 (-0.21%)
GSK : 41.35 (+0.27%)
PFE : 42.61 (+0.50%)
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

ABT : 75.08 (-0.23%)
JNJ : 136.08 (-0.22%)
GSK : 41.35 (+0.27%)
BMY : 51.36 (-0.60%)
Johnson & Johnson to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28th, at Lotte New York Palace, NY. Ashley McEvoy, Executive Vice President,...

JNJ : 136.08 (-0.22%)
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)

The Janssen Pharmaceutical Companies of Johnson & Johnson will present today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) early results from the ongoing Phase...

JNJ : 136.08 (-0.22%)
Vor Biopharma Completes $42 Million Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia

--Participation from Johnson & Johnson Innovation - JJDC, Novartis Institutes for BioMedical Research, Osage University Partners, and Vor Co-founder PureTech Health

JNJ : 136.08 (-0.22%)
NVS : 89.98 (+0.11%)
Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.

Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately...

JNJ : 136.08 (-0.22%)
Global Intraocular Lenses (Standard & Premium) Market, 2016-2019 & 2024 - Leading Players are Alcon, Bausch + Lomb, Carl Zeiss Meditec, Johnson & Johnson Vision Care

The "Intraocular Lenses - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

JNJ : 136.08 (-0.22%)
CZMWF : 92.8500 (-1.12%)
Global Nicotine Gum Market Report 2019-2023: British American Tobacco, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, and Novartis are Profiled

The "Global Nicotine Gum Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

BTI : 36.54 (-0.49%)
JNJ : 136.08 (-0.22%)
NVS : 89.98 (+0.11%)
GSK : 41.35 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 137.33
1st Resistance Point 136.86
Last Price 136.06
1st Support Level 135.46
2nd Support Level 134.53

See More

52-Week High 148.99
Fibonacci 61.8% 137.39
Last Price 136.06
Fibonacci 50% 133.81
Fibonacci 38.2% 130.22
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar